Claims for Patent: 8,636,787

Summary for Patent: 8,636,787

Title:	Method for expansion and deployment of polymeric structures including stents
Abstract:	The invention is to methods of deploying polymeric biodegradable or non biodegradable stents by use of stepwise creases in the pressure placed upon the inner diameter of the stent to slowly increase the stent diameter. In one embodiment, the pressure on the interior stent diameter is slowly increased. The stent is allowed to acclimate to this diameter for a set period of time, and then the pressure is again increased. This series of steps continues until the stent reaches its final diameter and a final period of acclimatization is maintained prior to the removal of the deployment/delivery device.
Inventor(s):	Sabaria; Patrick (Saint Nom, FR)
Assignee:	Arterial Remodeling Technologies, S.A. (Noisy le Roi, FR)
Application Number:	12/282,738
Patent Claims:	1. Method for deploying a stent to maintain the mechanical integrity and shape of the stent, said method comprising: I) forming a stent comprising at least one polymer, II) increasing the temperature of the stent to about 37.degree. C. for a period of time of at least about 60 seconds, III) introducing the stent into the duct or vessel, IV) increasing the pressure on the interior diameter of the stent, V) detecting the stent expansion, VI) maintaining the same pressure on the interior diameter of the stent for at least 10 seconds, without further expanding the stent, so that the stent acclimates, repeating steps (IV) through (VI) until the stent is at its final desired deployment diameter, and wherein step (III) may occur before, during or after step (II); wherein the temperature of the stent is maintained below its glass-transition temperature throughout steps (III)-(VI). 2. The method of step 1, whereby the at least one polymer is biodegradable. 3. The method of claim 2, wherein the at least one polymer is selected from the group consisting of: poly(L-lactide), polyglycolide, poly(D,L-lactide), copolymers of lactide and glycolide, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polytrimethylenecarbonate, polyorthoesters, polyanhydrides, polyphosphazenes, polylactic acid, polyglycolic acid, polyglactin, polyglyconate, lactic acid-based stereocopolymers, copolymers of lactic and glycolic acids, and Poly(lactic-co-glycolic-co-gluconic acid). 4. The method of claim 3, wherein said polymeric stent comprises poly(lactic) acid-polyethylene glycol (PLA-PEG) diblock co-polymers. 5. The method of claim 4, wherein said PLA-PEG diblock co-polymers are surface modifying agents. 6. The method of claim 1, wherein the glass transition temperature of the polymer is at least 37.degree. C. 7. The method of claim 1, wherein the glass transition temperature of the polymer is at least 45.degree. C. 8. The method of claim 1, wherein the glass transition temperature of the polymer is at least 57.degree. C. 9. The method of claim 1, wherein the polymer further comprises an anticoagulant agent or anti-inflammatory drug. 10. The method of claim 9, wherein said anticoagulant agent or anti-inflammatory drug is selected the group consisting of: heparin, anti-oxidants, vitamin E, compounds that regulate cellular proliferation, and corticosteroids. 11. The method of claim 1, wherein the polymer further comprises a compound that modulates wound healing. 12. The method of claim 11, wherein the at least one compound that modulates wound healing is selected from the group consisting of: proteases; vasoactive substances such as serotonin and histamine; fibronectin; collagenases; plasminogen activator; neutral proteases; elastin; collagens; proteogycans such as chondroitin-4-sulfate, dermaten sulfate and heparin sulfate; sulfated and non-sulfated glycosaminoglycans; epidermal growth factor (EGF); hormones such as estradiol, testosterone or progesterone; macrophage derived growth factor (MDGF); platelet derived growth factor (PDGF); thrombin; insulin; certain lymphokines; vascular endothelial growth factor (VEGF); fibroblast growth factors; co-factors such as iron, copper, and vitamin C; adrenomedullin; angiogenin; angiopoietin-1; angiopoitin-related growth factor; brain derived neurotrophic factor; corticotropin-releasing hormone; Cyr16; erythropoietin; follistatin; hepatocyte growth factor; interleukins (IL-3, IL-8); midkine; neurokinin A; neuropeptide Y (NPY); pleiotrophin; progranulin, prolifern; secretoneurin; substance P; transforming growth factor; VG5Q; factors that recruit pericytes; and becaplermin. 13. The method of claim 1, wherein the stent is increased to the temperature in step II) by use of heating in saline, the in vivo blood stream, or hot air. 14. The method of claim 1, wherein the stent is increased to the temperature in step II) for a period of time sufficient to transfer enough energy to allow chain mobility in step (IV), preferably about 60 to 300 seconds. 15. The method of claim 1, wherein step II) occurs before step III), introducing the stent into the duct or vessel. 16. The method of claim 1, wherein step IV) occurs by use of an inflationary device. 17. The method of claim 1, wherein step IV) occurs by use of heat transferring fluid. 18. The method of claim 1, wherein step V) occurs using medical imaging technology. 19. The method of claim 1, wherein the pressure on the stent in step VI) is maintained for 20 seconds. 20. The method of claim 1, wherein the increase in pressure of step IV) is an increase in one atmosphere. 21. The method of claim 1, wherein the time for the entire method to occur is at least fifty seconds. 22. A method for deploying a stent to maintain the mechanical integrity and shape of the stent, said method comprising: I) forming a stent comprising at least one polymer, II) increasing the temperature of the stent to about 37.degree. C. for a period of time of at least about 60 seconds, III) introducing the stent into the duct or vessel, IV) increasing the pressure on the interior diameter of the stent, V) detecting the stent expansion, VI) maintaining the same pressure on the interior diameter of the stent for at least 10 seconds, without further expanding the stent, so that the stent acclimates, repeating steps (IV) through (VI) in a step-wise manner until the stent is at its final desired deployment diameter, and wherein step (III) may occur before, during or after step (II); wherein the pressure is maintained for a period of at least about 30 seconds once the stent is at its final desired deployment diameter so that the stent acclimates to the final deployment diameter; wherein the temperature of the stent is maintained below its glass-transition temperature throughout steps (III)-(VI).

Details for Patent 8,636,787

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	12/16/1997		2039-03-29
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2039-03-29